Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Rani Therapeutics Holdings ( (RANI) ).
On June 20, 2025, Rani Therapeutics Holdings, Inc. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement for its Class A common stock, which has been below $1.00 for 30 consecutive business days. The company has until December 17, 2025, to rectify this by achieving a minimum bid price of $1.00 per share for at least 10 consecutive business days. If compliance is not regained, the company may transfer to The Nasdaq Capital Market for an additional compliance period. Failure to meet these requirements could result in delisting.
The most recent analyst rating on (RANI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.
Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.
To see Spark’s full report on RANI stock, click here.
More about Rani Therapeutics Holdings
Average Trading Volume: 443,107
Technical Sentiment Signal: Sell
Current Market Cap: $29.12M
Find detailed analytics on RANI stock on TipRanks’ Stock Analysis page.